Ross E. Blau

Associate

Contact

Practice Areas

Intellectual Property

Ross Blau is an associate in Axinn’s intellectual property group. His practice involves counseling and litigation for generic pharmaceutical products and biosimilar products, as well as mechanical devices, semiconductor technology, and other industries. His practice also includes litigation on complex antitrust cases involving intellectual property-related issues, such as price fixing, sham litigation, inequitable conduct, and standard-setting activity.

Ross E. Blau

Associate

New York

Contact

Practice Areas

Intellectual Property

Download PDF Download V-Card

Ross has also analyzed and litigated various regulatory issues, including those concerning FDA and the USPTO.

Ross’ experience also extends to copyright/trademark disputes and counseling regarding trade secrets. Further, Ross has worked on transactional issues involving analyses of various contractual terms with large potential stakes.

Ross has also developed various big data approaches to analyzing litigation and regulatory issues, including analyzing various product and patent portfolios to provide counseling to numerous companies.

Ross earned his JD at Washington and Lee University School of Law. During law school, Ross authored portions of an amicus brief submitted to the U.S. Supreme Court in Halo Elecs. Inc. v. Pulse Elecs. Inc. and Stryker Corp. v. Zimmer Inc. He holds an AB from The University of Chicago.

Experience

Represented Alvogen in a patent infringement and antitrust litigation regarding Indivior’s opioid dependency treatment drug Suboxone^® Film. The court denied a motion for summary judgment directed to Alvogen’s antitrust claim directed to exclusionary rebating practices. The case is the first of its kind in the pharmaceutical industry where the antitrust plaintiff was able to avoid summary judgment.
Representing Alvogen Inc. in the sprawling Generic Drugs MDL, a suit alleging participation in an industry-wide conspiracy to raise prices of generic medications through the allocation of markets.
Represented Norwich in a patent infringement action involving 18 patents and over 400 patent claims regarding Takeda’s (previously Shire’s) brand lisdexamphetamine capsules, Vyvanse^®.
Representing Norwich in a patent infringement action involving eight patents and 161 claims.

Honors

Super Lawyers, “Rising Stars” for IP Litigation (2023 – 2024)

Education

JD, cum laude – Washington and Lee University School of Law, Intellectual Property Fellow (2017)
AB, Honors – The University of Chicago (2013)

Admissions

New York
U.S. District Court Southern District of New York

Quotes

Their knowledge of the industry, law and implications is deep and thoughtful. The quality of the work...is first-rate.

Chambers USA

Their knowledge of the industry, law and implications is deep and thoughtful. The quality of the work...is first-rate.

Chambers USA

Their knowledge of the industry, law and implications is deep and thoughtful. The quality of the work...is first-rate.

Chambers USA

News & Insights

View all Insights

June 11, 2024

Court Orders Patents Delisted from Orange Book: Is FTC's Newly Aggressive Posture Having an Impact?

Over the past year, FTC has placed two sets of Orange Book listings in its crosshairs, but, to date, FTC has not actually begun any...

Axinn Viewpoints

Antitrust

April 30, 2024

FTC Expands Orange Book Patent Listing Challenges

As discussed in November and December, the FTC has placed improper Orange Book patent listings squarely in its crosshairs. Initially,...

Axinn Viewpoints

Intellectual Property

February 6, 2024

Lights, Camera, Action: GoPro’s Section 101 Arguments Head to the Federal Circuit

Tomorrow, the Federal Circuit will hear oral argument in Contour IP Holding LLC v. GoPro, Inc., Case Nos. 2022-1654, -1691, once again...

Axinn Viewpoints

Intellectual Property

May 15, 2023

Axinn IP Update: Supreme Court Denies Cert. in Skinny Label Case, but the Impacts from GSK v. Teva Continue

Today, the Supreme Court denied certiorari in Teva Pharms. USA, Inc. v. GlaxoSmithKline, LLC, 22-37, locking in the Federal Circuit’s second panel decision (hereafter “GSK v. Teva”), which held that Teva’s attempted section viii carveout of an indication covered by a patented method of use was not “skinny” enough to avoid being liable for infringement.

Publications

Intellectual Property

News & Insights

Related People

Chantelle D. Ankerman

Associate

Chantelle Ankerman is an associate in Axinn’s Intellectual Property group. Her practice focuses on intellectual property litigation and counseling, particularly in the fields of pharmaceuticals, biotechnology, and medical devices. Chantelle has litigated Hatch-Waxman Paragraph IV patent infringement suits and Section 337 Investigations at the International Trade Commission, as well as complex antitrust and commercial litigation matters. Chantelle also has experience drafting and prosecuting U.S. and international patent applications in relation to an assortment of medical device, electrical, mechanical, and computer technologies.

Learn more

Matthew J. Becker

Intellectual Property Practice Chair

Matt Becker is the Chair of the Intellectual Property practice and has over 25 years of experience trying and litigating a diverse range of patent infringement and trade secret cases. He has tried numerous high-stakes cases to both courts and juries.

Learn more

Rebecca L. Clegg

Counsel

Rebecca Clegg's practice focuses on complex intellectual property litigation and counseling, particularly in the fields of medical devices, pharmaceuticals, biotechnology, and semiconductors. Rebecca regularly litigates medical device and Hatch-Waxman Paragraph IV patent infringement suits. She also has experience representing clients in commercial litigation cases.

Learn more

Matthew S. Murphy

Partner

Matt Murphy leverages his prior experience as a research scientist to represent pharmaceutical, life sciences, and other companies in complex patent and trade secret litigation.

Learn more